vs

Side-by-side financial comparison of TScan Therapeutics, Inc. (TCRX) and XTI Aerospace, Inc. (XTIA). Click either name above to swap in a different company.

TScan Therapeutics, Inc. is the larger business by last-quarter revenue ($2.6M vs $2.5M, roughly 1.0× XTI Aerospace, Inc.). XTI Aerospace, Inc. runs the higher net margin — -541.3% vs -895.1%, a 353.8% gap on every dollar of revenue. On growth, TScan Therapeutics, Inc. posted the faster year-over-year revenue change (286.0% vs 170.6%). XTI Aerospace, Inc. produced more free cash flow last quarter ($-8.4M vs $-32.2M).

TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel T cell receptor (TCR) immunotherapies for hard-to-treat cancers. Its proprietary platform identifies high-affinity naturally occurring TCRs targeting tumor antigens, with pipeline candidates spanning hematological malignancies and solid tumors, operating in the global oncology therapeutics market.

Nextant Aerospace is a United States–based company specializing in the remanufacturing of business jets. Founded in 2007, Nextant is the first company to introduce the concept of aircraft remanufacturing to the business jet market.

TCRX vs XTIA — Head-to-Head

Bigger by revenue
TCRX
TCRX
1.0× larger
TCRX
$2.6M
$2.5M
XTIA
Growing faster (revenue YoY)
TCRX
TCRX
+115.4% gap
TCRX
286.0%
170.6%
XTIA
Higher net margin
XTIA
XTIA
353.8% more per $
XTIA
-541.3%
-895.1%
TCRX
More free cash flow
XTIA
XTIA
$23.8M more FCF
XTIA
$-8.4M
$-32.2M
TCRX

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
TCRX
TCRX
XTIA
XTIA
Revenue
$2.6M
$2.5M
Net Profit
$-23.0M
$-13.4M
Gross Margin
43.4%
Operating Margin
-929.4%
-596.2%
Net Margin
-895.1%
-541.3%
Revenue YoY
286.0%
170.6%
Net Profit YoY
35.8%
-203.2%
EPS (diluted)
$-0.18
$-0.61

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
TCRX
TCRX
XTIA
XTIA
Q4 25
$2.6M
Q3 25
$2.5M
$2.5M
Q2 25
$3.1M
$600.0K
Q1 25
$2.2M
$484.0K
Q4 24
$1.0M
Q3 24
$1.0M
$918.0K
Q2 24
$1.0M
Q4 23
$7.2M
Net Profit
TCRX
TCRX
XTIA
XTIA
Q4 25
$-23.0M
Q3 25
$-35.7M
$-13.4M
Q2 25
$-37.0M
$-20.9M
Q1 25
$-34.1M
$-12.9M
Q4 24
Q3 24
$-29.9M
$-4.4M
Q2 24
$-14.7M
Q4 23
$-19.6M
Gross Margin
TCRX
TCRX
XTIA
XTIA
Q4 25
Q3 25
43.4%
Q2 25
80.5%
Q1 25
69.2%
Q4 24
54.7%
Q3 24
56.6%
Q2 24
64.2%
Q4 23
Operating Margin
TCRX
TCRX
XTIA
XTIA
Q4 25
-929.4%
Q3 25
-1475.6%
-596.2%
Q2 25
-1256.6%
-1855.0%
Q1 25
-1669.7%
-2149.2%
Q4 24
Q3 24
-3109.8%
-459.3%
Q2 24
-1350.8%
Q4 23
-296.2%
Net Margin
TCRX
TCRX
XTIA
XTIA
Q4 25
-895.1%
Q3 25
-1422.1%
-541.3%
Q2 25
-1201.3%
-3476.3%
Q1 25
-1571.9%
-2659.5%
Q4 24
Q3 24
-2849.1%
-483.1%
Q2 24
-1426.8%
Q4 23
-272.0%
EPS (diluted)
TCRX
TCRX
XTIA
XTIA
Q4 25
$-0.18
Q3 25
$-0.28
$-0.61
Q2 25
$-0.28
$-2.93
Q1 25
$-0.26
$-3.80
Q4 24
Q3 24
$-0.25
$-33.40
Q2 24
$-261.99
Q4 23
$0.32

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
TCRX
TCRX
XTIA
XTIA
Cash + ST InvestmentsLiquidity on hand
$152.4M
$32.2M
Total DebtLower is stronger
$32.5M
Stockholders' EquityBook value
$123.1M
$10.5M
Total Assets
$228.8M
$47.9M
Debt / EquityLower = less leverage
0.26×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
TCRX
TCRX
XTIA
XTIA
Q4 25
$152.4M
Q3 25
$184.5M
$32.2M
Q2 25
$218.0M
$20.0M
Q1 25
$251.7M
$8.0M
Q4 24
$4.0M
Q3 24
$271.1M
$511.0K
Q2 24
$5.8M
Q4 23
$192.0M
Total Debt
TCRX
TCRX
XTIA
XTIA
Q4 25
$32.5M
Q3 25
$32.4M
Q2 25
$32.3M
$65.0K
Q1 25
$32.2M
$65.0K
Q4 24
$65.0K
Q3 24
$30.6M
Q2 24
Q4 23
$30.0M
Stockholders' Equity
TCRX
TCRX
XTIA
XTIA
Q4 25
$123.1M
Q3 25
$144.0M
$10.5M
Q2 25
$176.7M
$12.4M
Q1 25
$210.2M
$13.9M
Q4 24
$6.6M
Q3 24
$229.1M
$6.9M
Q2 24
$10.6M
Q4 23
$150.9M
Total Assets
TCRX
TCRX
XTIA
XTIA
Q4 25
$228.8M
Q3 25
$262.2M
$47.9M
Q2 25
$298.6M
$35.4M
Q1 25
$332.7M
$27.1M
Q4 24
$24.3M
Q3 24
$348.0M
$29.3M
Q2 24
$34.0M
Q4 23
$272.1M
Debt / Equity
TCRX
TCRX
XTIA
XTIA
Q4 25
0.26×
Q3 25
0.23×
Q2 25
0.18×
0.01×
Q1 25
0.15×
0.00×
Q4 24
0.01×
Q3 24
0.13×
Q2 24
Q4 23
0.20×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
TCRX
TCRX
XTIA
XTIA
Operating Cash FlowLast quarter
$-32.0M
$-8.4M
Free Cash FlowOCF − Capex
$-32.2M
$-8.4M
FCF MarginFCF / Revenue
-1253.3%
-338.0%
Capex IntensityCapex / Revenue
6.7%
0.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-139.7M
$-52.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
TCRX
TCRX
XTIA
XTIA
Q4 25
$-32.0M
Q3 25
$-32.5M
$-8.4M
Q2 25
$-33.3M
$-6.7M
Q1 25
$-37.6M
$-15.2M
Q4 24
$-22.3M
Q3 24
$-27.9M
$-6.1M
Q2 24
$-5.6M
Q4 23
$-23.8M
Free Cash Flow
TCRX
TCRX
XTIA
XTIA
Q4 25
$-32.2M
Q3 25
$-33.9M
$-8.4M
Q2 25
$-34.5M
$-6.8M
Q1 25
$-39.1M
$-15.3M
Q4 24
$-22.4M
Q3 24
$-29.3M
$-6.2M
Q2 24
$-5.7M
Q4 23
$-24.2M
FCF Margin
TCRX
TCRX
XTIA
XTIA
Q4 25
-1253.3%
Q3 25
-1349.6%
-338.0%
Q2 25
-1123.1%
-1133.2%
Q1 25
-1801.8%
-3158.5%
Q4 24
-2166.0%
Q3 24
-2792.0%
-670.0%
Q2 24
-548.0%
Q4 23
-336.1%
Capex Intensity
TCRX
TCRX
XTIA
XTIA
Q4 25
6.7%
Q3 25
56.8%
0.9%
Q2 25
41.6%
9.7%
Q1 25
70.6%
9.3%
Q4 24
6.6%
Q3 24
130.6%
3.9%
Q2 24
1.1%
Q4 23
6.5%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

TCRX
TCRX

Segment breakdown not available.

XTIA
XTIA

Short Term Contract With Customer$2.1M85%
Other$374.0K15%

Related Comparisons